Welcome to our dedicated page for Scisparc news (Ticker: SPRC), a resource for investors and traders seeking the latest updates and insights on Scisparc stock.
SciSparc Ltd. (Nasdaq: SPRC) generates news across clinical-stage pharmaceuticals, intellectual property, medical devices, and advanced computing initiatives. Through its majority-owned subsidiary NeuroThera Labs Inc., the company reports progress on cannabinoid-based drug candidates, patent grants, and collaborations targeting central nervous system and neuropsychiatric disorders.
Investors following SPRC news can expect updates on drug development programs such as SCI-110, for Tourette syndrome and for the treatment of Alzheimer’s disease and agitation, and SCI-210, for autism spectrum disorder (ASD) and status epilepticus. Company announcements also cover patent activity, including NeuroThera’s opioid–N-acylethanolamine platform for pain management and MEAI-based combination therapies for depression and addiction-related indications.
SciSparc’s news flow extends to corporate transactions and strategic repositioning. Recent disclosures include the transfer of its advanced clinical-stage pharmaceutical portfolio and its stake in SciSparc Nutraceuticals Inc. into NeuroThera Labs Inc., the sale of oncology-focused subsidiary MitoCareX Bio Ltd. to N2OFF, Inc., and a binding term sheet followed by a definitive agreement to acquire a treasury of patents and trademarks for innovative endoscopic systems and medical cameras, including the MUSE system for GERD treatment.
Another recurring theme in SPRC news is technology-driven R&D. The company has announced a quantum computing-enabled 3D protein modeling initiative aimed at improving drug discovery, as well as a non-binding term sheet for NeuroThera to acquire a majority stake in a quantum bio data analysis company. Regulatory and capital markets items, such as Nasdaq compliance notifications, warrant inducement agreements, and SEC Form 6-K filings, also appear in its news stream. For a structured view of these developments, the SciSparc news page aggregates press releases and related coverage in one place.
SciSparc Ltd. (NASDAQ: SPRC) announced the recruitment of its first patient for a Phase IIa clinical trial investigating the safety, tolerability, and efficacy of SCI-110 in treating Alzheimer's disease and associated agitation. Conducted at the Israeli Medical Center for Alzheimer's, the trial aims to provide an efficient treatment option amid limited existing therapies. SCI-110 combines synthetic Δ⁹-THC and Palmitoylethanolamide to address behavioral disturbances commonly observed in Alzheimer's patients, with the hope of improving their quality of life.
SciSparc Ltd. (NASDAQ: SPRC) announced a significant milestone with the granting of U.S. Patent No. 11,207,290, covering cannabinoid and N-acylethanolamine combinations for treating central nervous system disorders. This achievement is deemed crucial for the company, as it strengthens their intellectual property portfolio, now comprising four U.S. patents, along with similar patents in Australia and Japan. The patent emphasizes the uniqueness of their methodologies and compounds, reinforcing SciSparc's commitment to developing effective treatments for patients facing currently untreatable conditions.